Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Deutsche Bank Lowers Genentech Rating

Deutsche Bank downgraded its opinion on shares of Genentech (DNA) to market perform from buy.

Analyst Dennis Harp told Standard & Poor's MarketScope that the downgrade was based on two factors: 1) based on relative valuation - Genentech's p-e to growth rate vs. its peer group of profitable biotech companies -- the stock is trading at a multiple of 1.5 vs.the 0.8 average of its peer group; and 2) concerns regarding the upcoming Phase III data on the company's breast cancer drug. Harp says he is concerned that the primary endpoint -- a 50% improvement in time to progression -- may not be met. He says it is an aggressive goal. While he maintains his EPS estimates of $0.92 for 2002 and $1.01 for 2003, he slashed his $60 price target to $35.

blog comments powered by Disqus